ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer
ZoeNCure Therapeutics has licensed a proprietary antibody platform from Styx Biotechnologies to develop dual-payload antibody-drug conjugates for liver cancer. The partnership aims to address the high burden of hepatocellular carcinoma in India.
Why it matters
This collaboration represents a significant step in localizing advanced oncology research and improving targeted treatment options for specific cancer types in South Asia.
New Delhi, Delhi, India – Business Wire India
ZoeNCure Therapeutics Pvt. Ltd . , an oncology biotechnology company based in New Delhi, today announced a strategic licensing agreement with San Diego-based Styx Biotechnologies , Inc. Under the terms of the agreement, ZoeNCure has secured rights to license proprietary antibody technology and candidates to develop and commercialize next-generation antibody-drug conjugates (ADCs) in India.
The collaboration will focus primarily on developing novel dual-payload ADCs specifically designed for hepatocellular carcinoma (liver cancer), a widespread public health burden across India and South Asia with limited effective targeted treatment options.
By integrating licensed antibody targeting with advanced payload chemistries, ZoeNCure aims to engineer therapies that deliver two distinct therapeutic mechanisms simultaneously. This approach is designed to overcome treatment resistance, address tumor heterogeneity, and significantly enhance the therapeutic index compared to single-payload conjugates.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in